PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

Abstract

Authors

S. Branchoux S. Négrier C. de Peretti B. Malcolm J. May L. Marié A.F. Gaudin S. Klijn T.J. Ignacio